Skip to main content

Table 2 Adverse events from mTMZ that were tabulated during the study period

From: Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas

Adverse events Severity number of patients (%)
  Grade 1 & 2 Grade 3 & 4
Hematological
 Anemia 1 (11%) 0
 Leukopenia 2 (22%) 0
 Lymphopenia 2 (22%) 0
 Neutropenia 1 (11%) 0
 Thrombocytopenia 1 (11%) 0
 Fatigue 1 (11%) 0
Gastrointestinal
 Increased alkaline phosphatase 0 0
 Increased ALT 1 (11%) 1 (11%)
 Increased AST 1 ( 11%) 0
Infection
 Thrush 1 (11%) 0
 Zoster eruption 1 (11%) 0
Skin
 Petechial rash 1 (11%) 0